NICE draft guideline for cannabidiol for Dravet syndrome
27th August 2019
The NICE draft guidance for cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome is available for consultation until 16 September 2019.
NICE draft guideline for cannabidiol for Lennox-Gastaut syndrome
27th August 2019
The NICE draft guidance for cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome is available for consultation until 16 September 2019.
NICE draft guideline for Cannabis-based medicinal products
21st August 2019
The NICE draft guidance for Cannabis-based medicinal products is available for consultation. The consultation closes on 5 September 2019.
EMA adopts a positive opinion for Epidyolex
14th August 2019
The EMA has recommended that the EU grants a Marketing authorization (MA) for Epidyolex (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in conjunction with clobazam for patients >2 years age. Epidyolex is an oral solution of cannabidiol 100mg/mL.
Recent news
- Palliative Care Formulary available via the Association for Palliative Medicine (APM)
- NICE draft guideline for cannabidiol for Dravet syndrome
- NICE draft guideline for cannabidiol for Lennox-Gastaut syndrome
- NICE draft guideline for Cannabis-based medicinal products
- EMA adopts a positive opinion for Epidyolex
- Updated BTS/SIGN asthma guideline published
- Joint position statement on the decision by WHO to withdraw guidance documents
- Neuropathic pain in adults: updated NICE guidance
- BETTER- B breathlessness survey- last chance to complete
- Safer management of controlled drugs
News archive
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000